Access
To read this article in full you will need to log-in or choose from the options on the right.
Targets and Mechanisms - Metabolic disease
SciBX 1(45); doi:10.1038/scibx.2008.1094
Published online Dec. 18 2008
Extra navigation
Tyrosine kinase inhibitors for diabetes
by Brian Moy, Staff Writer
UCSF researchers have shown that Novartis' Gleevec and Pfizer's Sutent, two small molecule tyrosine kinase inhibitors, prevented and even reversed type 1 diabetes in mice. It remains to be seen whether short-term use of this drug class can actually produce long-term therapeutic benefits safely.
To read this article in full you will need to log-in or choose from the options on the right.
